



**International  
Conveyors  
Limited**

Corporate Office : 10, Middleton Row  
Post Box No. 9282, Kolkata - 700 071  
CIN : L21300WB1973PLC028854  
Facsimile : +91 - 33 - 2217 2269  
Phone : +91 - 33 - 4001 0061  
Mail : icltd@iclbeltng.com  
Url : iclbeltng.com

ICL/DS/2025-26/321

September 01, 2025

The Manager  
Listing Department  
National Stock Exchange of  
India Ltd  
Exchange Plaza,  
Plot No C-1, G Block,  
Bandra- Kurla Complex,  
Bandra (East),  
Mumbai-400051  
Symbol-INTLCONV

The General Manager  
Dept. Of Corporate Services  
BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai-400001  
Scrip Code-509709

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the International Conveyors Limited (“the Company”) has acquired the Equity shares of “Natco Pharma Ltd.”

The disclosure pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 read with Para A of Part A of Schedule III of the SEBI Listing Regulations, is attached as “**Annexure A**”.

We request you to kindly take the same on record.

Thanking You,  
Yours faithfully,  
For **International Conveyors Limited**

**Dipti Sharma**  
**Company Secretary & Compliance Officer**

Encl: As above



Registered Office & Works I :  
Falta SEZ, Sector - II, Near Pump House No. 3  
Village & Mouza - Akalmegh  
Dist. South 24 Parganas, West Bengal - 743 504

Works II :  
E-39, M.I.D.C. Area, Chikalthana  
Aurangabad - 431 006  
Maharashtra



**International  
Conveyors  
Limited**

Corporate Office : 10, Middleton Row  
Post Box No. 9282, Kolkata - 700 071  
CIN : L21300WB1973PLC028854  
Facsimile : +91 - 33 - 2217 2269  
Phone : +91 - 33 - 4001 0061  
Mail : icltd@iclbeltng.com  
Url : iclbeltng.com

### Annexure-A

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.:	<b>Name of the target entity:</b> Natco Pharma Ltd.  <b>Turnover as per last audited financials (FY 2024-25) :</b> 4429.5 Cr.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?  If yes, nature of interest and details thereof and whether the same is done at "arms length":	No
3.	Industry to which the entity being acquired belongs:	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	Investment Purpose
5.	Brief details of any governmental or regulatory approvals required for the acquisition:	N.A.
6.	Indicative time period for completion of the acquisition:	September 01, 2025
7.	Nature of consideration - whether cash consideration or share swap and details of the same:	Cash Consideration
8.	Cost of acquisition or the price at which the shares are acquired:	5.270 Crore



Registered Office & Works I :  
Falta SEZ, Sector - II, Near Pump House No. 3  
Village & Mouza - Akalmegh  
Dist. South 24 Parganas, West Bengal - 743 504

Works II :  
E-39, M.I.D.C. Area, Chikalthana  
Aurangabad - 431 006  
Maharashtra



# International Conveyors Limited

Corporate Office : 10, Middleton Row  
Post Box No. 9282, Kolkata - 700 071  
CIN : L21300WB1973PLC028854  
Facsimile : +91 - 33 - 2217 2269  
Phone : +91 - 33 - 4001 0061  
Mail : icltd@iclbeltng.com  
Url : iclbeltng.com

9.	Percentage of shareholding/ control acquired and/ or number of shares acquired:	60814 equity shares						
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	<p><b>Brief Background :</b></p> <p>Natco Pharma has grown into a global leader in niche pharmaceutical products. Its journey is defined by innovation, strategic growth, and a commitment to making specialty medicines accessible. With key breakthroughs in oncology and expansions into new markets, Natco continues to lead with agility and excellence.</p> <p><b>Turnover of last 3 Financial Years:</b> (Rs. in Cr.)</p> <table border="1"><thead><tr><th>F.Y. 24-25</th><th>F.Y. 23-24</th><th>F.Y. 22-23</th></tr></thead><tbody><tr><td>4429.5</td><td>3998.8</td><td>2707.1</td></tr></tbody></table> <p><b>Country in which the target has presence:</b></p> <p>India</p>	F.Y. 24-25	F.Y. 23-24	F.Y. 22-23	4429.5	3998.8	2707.1
F.Y. 24-25	F.Y. 23-24	F.Y. 22-23						
4429.5	3998.8	2707.1						



Registered Office & Works I :  
Falta SEZ, Sector - II, Near Pump House No. 3  
Village & Mouza - Akalmegh  
Dist. South 24 Parganas, West Bengal - 743 504

Works II :  
E-39, M.I.D.C. Area, Chikalthana  
Aurangabad - 431 006  
Maharashtra